KRAS and carcinoma: Furthermore, the c.34G>T tranversion comprises just 8% of KRAS2 mutations in sporadic and none in MSI-high CRCs.[12] In Lynch carcinomas the percentage of KRAS2 mutations is around 34%, Table 2 and 3) and in these carcinomas other hotspot mutations are found, namely the c.35G>A and c.38G>A, compromising 81% of detected KRA2S mutations in these tumours.